Clinical Trial Update: Trilaciclib Combined With Anti-PD-1 Antibody and Chemotherapy in the Treatment of Locally Advanced TNBC [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is investigating trilaciclib combined with an anti-PD-1 antibody and chemotherapy for locally advanced triple-negative breast cancer; t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Anti-PD-1 antibody
• Cosela (trilaciclib) (trilaciclib)

Snippet

Sponsor: QIAO LI | Conditions: Triple Negative Breast Cancer | Phase 2 | Status: RECRUITING